David A. Siegel Fibrogen Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Fibrogen Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 742,800 shares of FGEN stock, worth $297,120. This represents 0.0% of its overall portfolio holdings.

Number of Shares

742,800

Previous 1,187,600 37.45%

Holding current value

$297,120

Previous $1.06 Million 71.88%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $146,784 - $560,448	-444,800 Reduced 37.45%	742,800 $297,000
Q2 2024 Aug 14, 2024	SELL	$0.89 - $2.36 $14,863 - $39,412	-16,700 Reduced 1.39%	1,187,600 $1.06 Million
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $435,153 - $1.63 Million	-596,100 Reduced 33.11%	1,204,300 $2.83 Million
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.91 $63,726 - $152,607	167,700 Added 10.27%	1,800,400 $1.6 Million
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $667,629 - $2.39 Million	845,100 Added 107.3%	1,632,700 $1.4 Million
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $10,956 - $90,596	-4,400 Reduced 0.56%	787,600 $2.13 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $2.29 Million - $3.62 Million	143,700 Added 22.17%	792,000 $14.8 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $164,548 - $219,852	12,400 Added 1.95%	648,300 $10.4 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $535,800 - $686,200	-47,000 Reduced 6.88%	635,900 $8.27 Million
Q2 2022 Aug 15, 2022	SELL	$7.94 - $12.96 $1.06 Million - $1.74 Million	-133,900 Reduced 16.39%	682,900 $7.21 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $855,824 - $1.2 Million	-71,200 Reduced 8.02%	816,800 $9.82 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $1.21 Million - $1.87 Million	-121,400 Reduced 12.03%	888,000 $12.5 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $6.52 Million - $17.1 Million	640,800 Added 173.85%	1,009,400 $10.3 Million
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $3.58 Million - $6.88 Million	192,800 Added 109.67%	368,600 $9.82 Million
Q1 2021 May 17, 2021	BUY	$31.0 - $55.72 $1.22 Million - $2.2 Million	39,500 Added 28.98%	175,800 $6.1 Million
Q4 2020 Feb 16, 2021	SELL	$37.09 - $48.97 $1.62 Million - $2.14 Million	-43,600 Reduced 24.24%	136,300 $5.06 Million
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $2.36 Million - $2.65 Million	-58,300 Reduced 24.48%	179,900 $7.4 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $2.74 Million - $3.61 Million	84,200 Added 54.68%	238,200 $9.65 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $764,240 - $1.51 Million	-32,800 Reduced 17.56%	154,000 $5.35 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $221,312 - $307,584	6,400 Added 3.55%	186,800 $8.01 Million
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $525,116 - $687,990	14,200 Added 8.54%	180,400 $6.67 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $3.06 Million - $4.84 Million	87,100 Added 110.11%	166,200 $7.51 Million
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $64,245 - $89,865	-1,500 Reduced 1.86%	79,100 $4.3 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $1.07 Million - $1.7 Million	28,200 Added 53.82%	80,600 $3.73 Million
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $219,570 - $262,275	-3,900 Reduced 6.93%	52,400 $3.18 Million
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $709,420 - $1.03 Million	-15,800 Reduced 21.91%	56,300 $3.52 Million
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $1.22 Million - $1.65 Million	26,800 Added 59.16%	72,100 $3.33 Million
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $448,865 - $643,070	10,700 Added 30.92%	45,300 $2.15 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $1.16 Million - $1.86 Million	34,600	34,600 $1.86 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $37.5M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account